Oslo, Norway, April 3 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that the updated European Association of Urology guidelines on non-muscle invasive bladder cancer strengthen the recommended use of Hexvix photodynamic diagnosis. The guidelines also recognize the positive impact of Hexvix on reducing recurrence rate and improving time to recurrence of bladder cancer. Hexvix is Photocure’s flagship product to aid in the diagnosis and management of bladder cancer.
Kjetil Hestdal, President and Chief Executive Officer of Photocure, commented: “We are very pleased that the updated guidelines further reinforce the benefits of using Hexvix in the diagnosis and management of non-muscle invasive bladder cancer. The recognition that Hexvix reduces the recurrence rate and improves the time to recurrence of bladder cancer is significant for urologists and patients suffering from this disease.”
The EAU Guidelines on Non-muscle-invasive Bladder Cancer can be accessed at http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR.pdf
Hexvix is the first approved drug-device combination procedure for improved detection and management of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic (PDD) agents. Hexvix is an approved product in Europe and the US. Photocure markets and sells Hexvix in the Nordic region, and has initiated the commercialization of Cysview directly in the US. Ipsen is commercializing Hexvix in Europe excluding Nordics.
About Photocure ASA
Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology™ platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.
For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: email@example.com
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: firstname.lastname@example.org